Pfizer Says ELREXFIO Phase 3 Trial Met Primary PFS Endpoint
Pfizer said MagnetisMM-32 met its primary endpoint, with ELREXFIO monotherapy reducing the risk of progression or death versus three standard regimens in RRMM. PFS was 68% at 18 months; median PFS was not yet reached. Overall survival data remain immature, and regulatory filings are planned.
Pfizer said Phase 3 MagnetisMM-32 met its primary endpoint, with ELREXFIO monotherapy reducing risk of progression or death vs three standard regimens in RRMM; 68% PFS at 18 months and median PFS not yet reached. OS data are immature; filings to regulators are planned.Material DetailsContext by AI…